lymphocytes

[Science] Scientists determined that complement component 3 bound to peptide-loaded major histocompatibility complex class II molecules exposed on the surface of mouse and human conventional dendritic cells, forming a covalent bond with the carbohydrate moiety of the MHC II α chain.

[Oncogene] Scientists created type I interferon (IFN)α-overexpressing MSCs. Upon direct injection into tumors, they found that these cells were powerful in eliminating several types of tumors.

[Clinical Cancer Research] Digital image analysis of whole section slides was used to assess abundance and spatial distribution of T cells and tertiary lymphoid structures in the tumor immune microenvironment of 117 tumor samples.

[Minerva Biotechnologies] Minerva Biotechnologies Corporation announced that its trial of huMNC2-CAR44 T cells has now opened at City of Hope, Duarte, California. This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1*, the transmembrane cleavage product that is a growth factor receptor that drives growth of an estimated 93% of breast cancers.

[Neurochemical Research] Researchers explored the mechanism of hUC-MSC derived exosome's ameliorative effect on the spinal cord injury by combining data from in vivo contusion spinal cord injury model and in vitro cell viability of PC12 cell line stimulated with lipopolysaccharide.

[Science Advances] Combining crystallography, glycobiology, and functional B cell assays allowed researchers to dissect key characteristics of variable domain glycans on human B cell biology.